For the quarter ended June 2025, Privia Health (PRVA) reported revenue of $521.15 million, up 23.4% over the same period last year. EPS came in at $0.02, compared to $0.03 in the year-ago quarter.
The reported revenue represents a surprise of +11.24% over the Zacks Consensus Estimate of $468.49 million. With the consensus EPS estimate being $0.05, the EPS surprise was -60%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Privia Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Practice Collections: $862.9 million versus the five-analyst average estimate of $804.11 million.
- Care Margin: $115.2 million versus the five-analyst average estimate of $109.25 million.
- Platform Contribution: $57.5 million compared to the $52.25 million average estimate based on five analysts.
- Implemented Providers (as of end of period): 5,125 versus 4,967 estimated by two analysts on average.
- Value-Based Care Attributed Lives (as of end of period): 1.38 million versus the two-analyst average estimate of 1.3 million.
View all Key Company Metrics for Privia Health here>>>
Shares of Privia Health have returned -6.7% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Privia Health Group, Inc. (PRVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
